[ad_1]
Lung cancer is considered a difficult cancer in cancer. According to statistics on the causes of death of the National Bureau of Statistics, lung cancer has never been described as "number one cancer of domestic mortality" over the last 13 years (2004-2016).
High-risk patients, including those with lung cancer, chronic lung disease, and smokers in the family, routinely undergo low-dose computed tomography (CT) scans. The early detection rate is 2.6 times higher. The Department of Health and Wellness conducts a free lung cancer screening trial using low-dose CT for 8,000 high-risk smokers aged 55 to 74 years old for up to two years. this year to reduce the mortality rate by early detection and treatment of lung cancer.
As a clinician in internal medicine who must experience sad stories of patients at the actual treatment site, we welcome the addition of lung cancer to the national cancer screening project . In fact, a survey of 183 lung cancer experts found that 95% would increase the lung cancer survival rate after the introduction of the National Cancer Screening Project.
In addition to medical technology, anticancer drugs have grown remarkably. Recently, the emergence of anticancer drugs has led to innovative changes in the history of chemotherapy. As a representative example, in the case of non-small cell lung cancer, which accounts for approximately 80% of lung cancer, immunotherapy has been approved as a first-line treatment for advanced non-small lung cancer. cells and has been evaluated as a new chemotherapeutic paradigm. Recently, the National Cancer Network (NCCN) of the United States, an international standard practice guide on cancer, recommends immunotherapy as a first-line treatment for new non-small cell lung cancer. In Korea, immunocompromised cancer drugs have been approved by the Food and Drug Administration as a first-line treatment for non-small cell lung cancer, and patients with non-small cell lung cancer can begin their treatment.
In recent decades, chemotherapy was the only treatment for more than half of patients with advanced non-small cell lung cancer. There were few patients who experienced serious side effects such as vomiting, hair loss, or who dropped out of treatment or died. However, the use of immunotherapy instead of chemotherapy for the first time in patients with this disease, overall survival more than twice as long and the treatment of pain and improve the quality of life has been confirmed recently, He hopes a standard treatment.
However, in Korea, which is the basis of the state-run insurance system, it is difficult to prescribe patients without insurance benefits. For example, even if it is expected that a patient has an immunosuppressive effect in the first treatment, it is difficult to pay expensive treatment costs. In fact, there are few patients who undergo general chemotherapy for the second immunotherapy that can provide insurance benefits. This is because of the reality that it is inevitable to apply chemotherapy that can be paid first, although there is a treatment that should have a better effect.
In order to defeat lung cancer, institutional support for the treatment of most patients with lung cancer discovered after the progression of the disease should be supported as well as a national screening for early diagnosis.
[ad_2]
Source link
